Has Timothy Aksamit, MD received payments from drug or device companies?

Yes. Drug and device makers reported $25,703 in general payments to Timothy Aksamit, MD across 30 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Timothy Aksamit, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Timothy Aksamit, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Timothy Aksamit, MD

Pulmonary Disease · Rochester, MNNPI 1184694770

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,089 of the $25,703 with a category attached, or 85.9%. 5 manufacturers reported payments, led by Advanced Respiratory, Inc at 38.5% of the total. Reporting peaked in 2020 at $14,634 and has fallen 79.2% since, to $3,047 in 2024. Among pulmonary disease clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,703in general payments, 2019–2025

Across 30 payments — averaging $856.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Advanced Respiratory, Inc$10K
Insmed, Inc.$9K
Astrazeneca UK Limited$4K
Grifols Shared Services North America, Inc.$3K
Zambon USA Ltd.$32

$956,033in research payments, 2019–2025

Across 714 payments — averaging $1338.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Insmed, Inc.$860K
Verona Pharma, Inc.$57K
AstraZeneca$19K
Janssen Research & Development, LLC$14K
Boehringer Ingelheim International GmbH$5K

What the payments were for

Consulting fees$22,08986%
Travel & lodging$3,14112%
Food & beverage$4532%
Education$210%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Advanced Respiratory, Inc	7	$9,889
Insmed, Inc.	19	$8,703
Astrazeneca UK Limited	2	$4,279
Grifols Shared Services North America, Inc.	1	$2,800
Zambon USA Ltd.	1	$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

The Monarch Airway Clearance System$9,826
The Vest System 205 Acute Care$9,426
The Vest System Model 105 Home Care$9,426
FASENRA$4,279
Xembify$2,800
Arikayce$450

How this compares

$25,703 in reported general payments places this provider in the 95th percentile of 261 pulmonary disease providers in Minnesota.

See all pulmonary disease providers in Minnesota →

Medicare billing

Part B allowed, 2024

$93,018

Medicare patients

674

Services billed

1,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ColistimethateColistin (Colistimethate Na)	38	$18,551
Breo ElliptaFluticasone/Vilanterol	14	$7,248
Stiolto RespimatTiotropium Br/Olodaterol Hcl	11	$6,230
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	32	$3,990
Advair DiskusFluticasone Propion/Salmeterol	11	$3,601
Albuterol Sulfate HfaAlbuterol Sulfate	68	$2,295
Ethambutol Hcl	46	$1,600
Rifampin	26	$794
Ipratropium Bromide	27	$729
Famotidine	51	$639
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	37	$615
Azithromycin	37	$533
Levofloxacin	25	$346
Fluticasone Propionate	19	$228
Omeprazole	21	$214

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Rochester

Hilary DubrockRochester$102K
Ulrich SpecksRochester$77K
Jagdeep BijwadiaRochester$54K
Teng MouaRochester$47K
Michael KrowkaRochester$25K
Kaiser LimRochester$18K
Robert VassalloRochester$18K
Eva Carmona PorqueraRochester$17K
Tobias PeikertRochester$10K
Joseph SkalskiRochester$8K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →